



Biomega Appoints Espen Aarstad as New CFO

22.02.2021

Biomega Group ('Biomega'), a leading biosciences company producing high-quality and sustainable salmon ingredients for the human and pet health sectors, has announced the appointment of Espen Aarstad as its new Chief Financial Officer.

Aarstad, who has been working as the company's interim CFO since last Autumn, will now move into the role in an official capacity on 1st March 2021. He joins Biomega following a 20-year career in finance, where he held multiple positions in leading manufacturing companies, including Group CFO at Totaltek AS in Oslo and Protan AS in Norway.

"It is a pleasure to join the Biomega team, particularly as the company accelerates its 2021 strategic plans," Aarstad commented. "Biomega has seen rapid growth in the past couple of years and I'm truly excited to be involved in such an ambitious investment strategy. This year will see the Biomega brand achieve new heights in performance as we investigate the numerous health opportunities for human grade salmon ingredients."

The news of Aarstad's appointment completes the Norwegian-based company's leadership team and follows the announcement of Stig Victor Petersen as CEO last October. Aarstad will take a pivotal position in the company as Biomega continues to invest in its proprietary R&D technology as part of an ambitious expansion strategy, exploring upcoming opportunities in the human nutrition market.

Petersen added: "Since Espen stepped in as interim CFO last year, he has provided the leadership team with accelerated business insight based on a wealth of knowledge obtained through previous positions. His strong financial capabilities, combined with a passion for biotechnology and manufacturing, will provide us with great direction as we move further into 2021. We are pleased to welcome Espen in an official capacity to our team."

The company's current strategy remains unchanged, with continued focus on advancing biotechnology to release the full nutritional and functional value of underutilised side streams in the salmon industry.

For more information on Biomega and its activities, please visit <https://biomegagroup.com/>.

About Biomega Group

The Biomega Group aspires to become the leading partner for innovative high-quality ingredients to the health & nutrition industry. Biomega's business model is fully sustainable and uses proprietary biotech to transform high quality raw material into premium food and feed ingredients. In its modern food grade biorefinery in Norway, Biomega produces hydrolyzed salmon proteins (salmon peptides), salmon meal and salmon oil. Biomega invests continuously in R&D to ensure best-in-class technology and respond to customers' needs, including traceability and sustainability. The Biomega Group is a portfolio company of AMERRA Capital Management.

About AMERRA Capital Management

AMERRA is an independent asset management firm, providing strategic capital to upstream and midstream food and agri-businesses in Europe and the Americas. AMERRA brings unique value to its portfolio



companies through its extensive network, in depth knowhow and a sole focus on the field. Throughout its dedicated strategies of private credit, special situations, and private equity, AMERRA adheres to best Environmental & Social practices and belongs to the United Nations Environment Program – Finance Initiative. Backed by long-term institutional capital with more than US\$ 1.7bn in assets under management, AMERRA has invested over \$5.2 billion since its inception in 2009. For more information about AMERRA please visit www.amerracapital.com.

Contact

David Gould
Head of Investor Relations and Capital Markets
AMERRA Capital Management
+1 (212) 710-8023
dgould@amerracapital.com